Publicidad
Caso clínico 07 de enero de 2014

Hallazgo con 18F-FDG PET/CT de metástasis adrenal y cerebelosa no sospechadas en una paciente con metástasis pulmonares de cáncer colorrectal

Referenciar Imprimir Descargar PDF

Referencias

  1. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
  2. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001;13:275-86.
  3. Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4): iv61–3.
  4. Yoo PS, Lopez-Soler RI, Longo WE, et al. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202–7.
  5. Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum 1999;42:1592-7.
  6. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-705.
  7. Cedermark BJ, Blumenson LE, Piickren JW, et al. The significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977;144:537-46.
  8. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: http://globocan.iarc.fr, accesado 20/12/13.
  9. Gonzalez M, Ris HB, Krueger T, et al. Colorectal cancer and thoracic surgeons: close encounters of the third kind. Exp Rev Anticancer Ther 2012;12:495–503.
  10. Gonzalez M, Poncet A, Combescure C, et al. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013;20:572-9.
  11. Sanli Y, Kuyumcu S, Ozkan ZG, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med 2012;26:551-8.
  12. Kim SH, Brennan MF, Russo P, et al. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 1998;82:389-94.
  13. Katayama A, Mafune K, Makuuchi M. Adrenalectomy for solitary adrenal metastasis from colorectal carcinoma. Jpn J Clin Oncol 2000;30:414–6.
  14. Watatani M, Ooshima M, Wada T, et al. Adrenal metastasis from carcinoma of the colon and rectum: A report of three cases. Jpn J Surg 1993;23:444-8.
  15. O’Connor OJ, McDermott S, Slattery J, et al. The use of PET-CT in the assessment of patients with colorectal carcinoma. Int J Surg Oncol 2011:846512.
  16. Blake MA, Prakash P, Cronin CG. PET/CT for adrenal assessment. Am J Roentgenol 2010;195:W91-5.
  17. Wroński M, Arbit E. Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 1999;85:1677–85.
  18. Metser U, You J, McSweeney S, et al. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. Am J Roentgenol 2010;194:766–71.
  19. Hammoud MA, McCutcheon IE, Elsouki R, et al. Colorectal carcinoma and brain metastases: distribution, treatment and survival. Ann Surg Oncol 1996;3:453–63.
  20. Gundgaard MG, Soerensen JB, Ehrnrooth E. Third-line therapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2008;61:1-13.